Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Real World Study of Laparoscopic Preservation of the Pylorus Gastrectomy

8 listopada 2019 zaktualizowane przez: RenJi Hospital

A Real World Study of the Effect of Laparoscopic Preservation of the Pylorus and Vagus Nerve on the Postoperative Quality of Life in Patients With Early Gastric Cancer

For the patients with early gastric cancer (T1), preoperative evaluation (gastroscope, ultrasound gastroscope and abdominal enhanced CT) showed that the tumor was located in the body of the stomach, and the margin was enough to retain the pylorus and non lymph node metastasis (N0). Lappg (D1 + lymph node dissection) and traditional laparoscopic distal gastrectomy (BII type anastomosis, D1 + lymph node dissection) were included A control study was conducted to evaluate the difference of long-term quality of life, gastric emptying rate, incidence of basic reflux gastritis, bile contraction function, immune index, nutritional index and disease-free survival and overall survival between the two groups.

Przegląd badań

Status

Jeszcze nie rekrutacja

Warunki

Interwencja / Leczenie

Szczegółowy opis

The overall design of this study is an experimental study based on the real world. All the patients in the study group were from early gastric cancer patients who were operated on in gastrointestinal surgery of Renji Hospital. According to the preoperative evaluation of early gastric cancer (gastroscope, ultrasonic gastroscope and abdominal enhanced CT), patients with early gastric cancer whose tumor is located in the gastric body and whose cutting edge is enough to retain pylorus and non lymph node metastasis (N0) were included in the study. Group A (Study Group): lappg treatment group, group B (control group): laparoscopic distal gastrectomy type I group. In this study, group A was taken as the study group and group B as the control group Group, the differences between groups were compared. The main end point was the quality of life score (eortc-qlq-c30 scale, see the attached table). According to the literature and the data of the retrospective study of the center, it was assumed that the expected mean of the study group after treatment was 7.27, the mean of the control group after treatment was 6.76, and the total standard deviation of the test group and the control group was 0.51. The design of the test group and the control group was 1:1. According to this, two independent α = 0.05 were carried out Test of the average number of standing samples. It is calculated that 144 patients (72 in each group) are needed, so that under the test level of α = 0.05, according to 80% test efficiency, the difference between the two groups is statistically significant. Assuming that 10% of the patients could not be evaluated (shedding), 80 patients in each group were enrolled, and 160 patients in both groups were enrolled.

2) inclusion / exclusion / withdrawal criteria of subjects

Inclusion criteria: 18 years old < age < 75 years old; primary gastric lesions were diagnosed as gastric adenocarcinoma by tissue biopsy; preoperative clinical stage was T1N0M0 according to ajcc-7thtnm tumor stage; the tumor site was expected to receive R0 after pylorus preserving gastrectomy and D1 + lymph node dissection; preoperative Eastern Cooperative Oncology Group physical state score was 0 / 1; preoperative ASA score was I-III, with informed consent of the patient.

Exclusion criteria: pregnant or lactating women; severe mental illness; history of upper abdominal surgery (except for laparoscopic cholecystectomy); history of gastric surgery (including endoscopic submucosal dissection/ endoscopic mucosal resection for gastric cancer); preoperative imaging examination showed regional enlarged lymph nodes; history of other malignant diseases within 5 years; patients with gastric cancer who have implemented new adjuvant treatment or recommended new adjuvant treatment; no History of stable angina pectoris or myocardial infarction; history of cerebral infarction or cerebral hemorrhage within 6 months; history of continuous systemic corticosteroid therapy within 1 month; simultaneous operation for other diseases; emergency operation for gastric cancer with complications (hemorrhage, perforation, obstruction).

Withdrawal criteria: conversion to laparotomy; intraoperative / postoperative pathological confirmation of tumor invasion depth exceeding T1, or tumor invasion of duodenum; intraoperative / postoperative pathological confirmation of lymph node metastasis; intraoperative / postoperative pathological confirmation of M1 cases; intraoperative confirmation of failure to complete D1 + lymph node dissection / R0 due to tumor reasons; intraoperative confirmation of the need for total gastrectomy to ensure safe proximity; need for other diseases During the same period of the study, the patients were operated at the same time; because of severe complications (unable to tolerate surgery or anesthesia) during the perioperative period, the treatment plan of the study was not suitable or could not be implemented according to the plan; after entering the study, because of the patient's condition change, the emergency operation was confirmed by the doctor in charge; at any stage after entering the study, the patients voluntarily requested to withdraw or suspend the treatment due to the patient's personal reasons Treatment; treatment proven to be in violation of this protocol.

3) end point of study

Primary endpoint: 5-year quality of life assessment [time window: 5 years after operation]. Secondary endpoint: 3-year quality of life [time window: 3 years after operation]; immune index [time window: 5 years after operation]; nutritional index [time window: 5 years after operation]; gastric emptying rate [time window: 5 years after operation]; incidence of basic reflux gastritis [time window: 5 years after operation]; gallbladder contraction function [time window: 5 years after operation]; 5-year total survival rate [time window: 5 years after operation] 5 years; 5-year recurrence free survival [time window: 5 years after operation].

4) diagnostic criteria for this study

In this study, ajcc-7th primary tumor, regional nodes, metastasis tumor staging system was used; the diagnostic criteria and classification of gastric cancer were based on the international diagnostic criteria of histopathology; the definition of early gastric cancer: tumor infiltration was limited to the mucosa and submucosa, and did not invade the muscular layer (T1); in this study, T1N0 was the study object, but not the study object.

5) interventions

According to the preoperative evaluation (gastroscope, ultrasonic gastroscope and abdominal enhanced CT), the tumor is located in the body of the stomach, and the cutting edge is enough to retain the pylorus and early gastric cancer without lymph node metastasis (N0). By randomized grouping, the laparoscopic pylorus preserving gastrectomy (lappg, D1 + lymphadenectomy) and traditional laparoscopic distal gastrectomy (BII type anastomosis, D1 + lymphadenectomy) are performed Bed operation intervention.

6) statistical analysis

In demographic indicators, numerical variables are mainly described by means of means and standard deviations, and classified variables are mainly described by rates or ratios. T-test, chi square test or nonparametric test can be used to test the equilibrium of two groups of demography.

Statistical analysis method of main index and secondary index. The main index is patients' postoperative quality of life score (postscript symptom scores), which is a numerical variable. The statistical description mainly uses mean and standard deviation. Statistical inference uses t-test, ANOVA or nonparametric test according to data distribution conditions. The secondary indicators involve the expression of usage rate of classified statistical description, and the expression of chi square test of statistical inference hypothesis test. If there is no balance between the two groups, we can use multiple regression to adjust the confounding factors and compare the difference between the two groups.

Typ studiów

Obserwacyjny

Zapisy (Oczekiwany)

160

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat do 75 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Metoda próbkowania

Próbka prawdopodobieństwa

Badana populacja

For the patients with early gastric cancer (T1), preoperative evaluation (gastroscope, ultrasound gastroscope and abdominal enhanced CT) showed that the tumor was located in the body of the stomach, and the margin was enough to retain the pylorus and non lymph node metastasis (N0). Lappg (D1 + lymph node dissection) and traditional laparoscopic distal gastrectomy (BII type anastomosis, D1 + lymph node dissection) were included A control study was conducted to evaluate the influence of two surgical methods on the long-term quality of life of patients after operation

Opis

Inclusion Criteria:

1) 18 years old < age < 75 years old;

(2) primary gastric lesions were diagnosed as gastric adenocarcinoma by biopsy;

(3) the preoperative clinical stage was T1N0M0 according to ajcc-7thtnm;

(4) it is predicted that R0 can be obtained by pylorogastric gastrectomy and D1 + lymph node dissection;

(5) preoperative ECoG physical state score 0 / 1;

(6) preoperative ASA score I-III;

(7) informed consent of patients.

Exclusion Criteria:

  1. pregnant or lactating women; suffering from serious mental illness;
  2. the history of upper abdominal surgery (except laparoscopic cholecystectomy);
  3. history of gastric surgery (including ESD / EMR for gastric cancer);
  4. preoperative imaging examination showed regional enlarged lymph nodes;
  5. having other malignant diseases within 5 years;
  6. patients with gastric cancer who have received new adjuvant therapy or recommended new adjuvant therapy;
  7. there was a history of unstable angina or myocardial infarction within 6 months;
  8. have a history of cerebral infarction or cerebral hemorrhage within 6 months;
  9. there was a history of continuous systemic corticosteroid therapy within 1 month;
  10. simultaneous surgical treatment of other diseases is needed;
  11. gastric cancer with complications (hemorrhage, perforation, obstruction) requires emergency surgery;
  12. FEV1 of pulmonary function examination was less than 50% of the predicted value.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

Kohorty i interwencje

Grupa / Kohorta
Interwencja / Leczenie
lappg
Laparoscopic gastrectomy for pylorus preservation
ladgbi
Laparoscopic gastrectomy for pylorus preservation

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
EORTC Questionnaire QLQ-C30
Ramy czasowe: 5 years
Among the multiple tools to evaluate QOL of postgastrectomy patients, the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30 have been used most extensively.
5 years

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Oczekiwany)

1 stycznia 2020

Zakończenie podstawowe (Oczekiwany)

1 stycznia 2022

Ukończenie studiów (Oczekiwany)

1 stycznia 2025

Daty rejestracji na studia

Pierwszy przesłany

4 listopada 2019

Pierwszy przesłany, który spełnia kryteria kontroli jakości

8 listopada 2019

Pierwszy wysłany (Rzeczywisty)

13 listopada 2019

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

13 listopada 2019

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

8 listopada 2019

Ostatnia weryfikacja

1 listopada 2019

Więcej informacji

Terminy związane z tym badaniem

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Rak żołądka

Badania kliniczne na lappg

3
Subskrybuj